- Report
- July 2023
- 210 Pages
Global
From €4324EUR$4,500USD£3,697GBP
- Report
- October 2023
- 85 Pages
United States
From €4564EUR$4,750USD£3,902GBP
- Report
- October 2023
- 122 Pages
North America
From €4228EUR$4,400USD£3,614GBP
- Report
- October 2023
- 138 Pages
North America
From €4228EUR$4,400USD£3,614GBP
- Report
- November 2023
- 164 Pages
Middle East, Africa
From €1441EUR$1,500USD£1,232GBP
- Report
- July 2023
- 147 Pages
Middle East, Africa
From €1441EUR$1,500USD£1,232GBP
- Report
- June 2020
- 280 Pages
Global
€1990EUR$2,219USD£1,761GBP
- Report
- November 2020
- 450 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Report
- February 2022
- 84 Pages
Global
From €1248EUR$1,299USD£1,067GBP
- Report
- September 2021
- 178 Pages
Global
From €4611EUR$4,799USD£3,942GBP
- Report
- January 2021
- 205 Pages
Global
From €5284EUR$5,499USD£4,517GBP
- Report
- August 2021
- 630 Pages
Global
From €4611EUR$4,799USD£3,942GBP
- Report
- February 2020
- 360 Pages
Global
From €4707EUR$4,899USD£4,024GBP
- Report
- April 2022
- 180 Pages
Global
From €2690EUR$2,800USD£2,300GBP
- Report
- November 2022
- 130 Pages
Global
From €1730EUR$1,800USD£1,479GBP
- Report
- June 2022
- 1500 Pages
Global
From €3747EUR$3,900USD£3,204GBP
- Report
- May 2023
- 1500 Pages
China
From €4900EUR$5,100USD£4,189GBP
- Report
- May 2022
- 510 Pages
Global
From €2883EUR$3,000USD£2,464GBP
- Drug Pipelines
- March 2022
- 900 Pages
Global
From €8648EUR$9,000USD£7,393GBP
- Report
- February 2022
- 360 Pages
United States
From €3459EUR$3,600USD£2,957GBP
Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs.
Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more